Wave Life Sciences Ltd. reported its financial results for the second quarter of 2026, revealing a significant decline in revenue and an increase in operating losses compared to the same period last year. The company generated $2.3 million in revenue for the three months ended June 30, 2026, a decrease of 74% from $8.7 million in the same quarter of 2025. For the six-month period, revenue increased to $40.5 million from $17.9 million, primarily due to the recognition of deferred revenue related to the alpha-1 antitrypsin deficiency (AATD) program, which was fully satisfied upon the termination of the AATD license.
Operating expenses for the second quarter rose to $76.1 million, up from $61.5 million in the prior year, driven by increased research and development costs, which totaled $51.3 million, compared to $43.5 million in 2025. General and administrative expenses also increased to $24.8 million from $18.0 million. The net loss for the quarter was $69.4 million, compared to a loss of $50.5 million in the same quarter of the previous year. For the first half of 2026, the net loss was $95.4 million, slightly improved from a loss of $97.3 million in the first half of 2025.
In terms of strategic developments, Wave Life Sciences is advancing its clinical pipeline, which includes programs targeting obesity, AATD, and liver disease. The company has also undergone a corporate restructuring, planning to redomicile from Singapore to Delaware, which is expected to take effect in August 2026. This move aims to streamline operations and enhance its corporate governance structure. Additionally, the company extended its lease for its manufacturing facility in Lexington, Massachusetts, securing the space through January 2038 to support its ongoing development activities.
As of June 30, 2026, Wave Life Sciences reported cash and cash equivalents of $368.0 million, along with marketable securities of $122.6 million. The company anticipates that its existing cash resources will be sufficient to fund operations for at least the next twelve months. However, it cautions that it may need to raise additional capital to support its ongoing research and development efforts, as it has not yet generated product revenue and continues to incur significant operating losses.
Looking ahead, Wave Life Sciences remains focused on advancing its RNA medicines platform, PRISM, and expects to continue incurring substantial expenses as it conducts clinical trials and develops new product candidates. The company is also exploring potential collaborations and partnerships to enhance its pipeline and financial position, while navigating the challenges of the biotechnology industry, including regulatory approvals and market competition.
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd. is a biotechnology company specializing in RNA-based therapeutics using its proprietary PRISM platform. It develops innovative oligonucleotide medicines across modalities like RNA editing, splicing, and silencing to treat rare and common diseases. Its pipeline includes programs for obesity, genetic liver disorders, muscular dystrophy, and neurodegenerative diseases, leveraging chemistry innovations for targeted, durable, and delivery-efficient RNA therapies.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov